Clinical Research On The Treatment Of Decompensated Hepatitis B Cirrhosis With Roumudan Keli And Adefovir Dipivoxil

Objective:To observe the clinical effect and security of the Roumudan Keli and Adefovir dipivoxil in treating cirrhotic patients following chronic hepatitis B with Qi asthenia blood stasis and toxic retention, all of them were in compenstory stage. And to explore its preliminary mechanism. and provide the basis for their clinical application.Methods:Choose the 80 patients with standard and they were randomly divided into treatment group and control group, each with 40 patients. In the course of treatment, two cases were lost in the treatment group,three cases were lost in the control group. Collected a total of 75 cases of complete cases.In the treatment group,patients were given 10mg of adefovir dipivoxil and 3 packages of Roumudan Keli, required to take. In the control group,patients were only given 10mg of adefovir dipivoxil.Both group were observated 48 weeks. During the medication, the patients should pay attention to rest, not allowed to drink. The patients were continued to given adefovir dipivoxil after the end of observision.At the end, observed a number of indicators about the patients before and after treatment,such as symptoms,signs, liver function, endoscopy, indicators of liver fibrosis,HBV-DNA load, B-type ultrasonic of upper abdomen.Results:After treatment,the two groups both have a good effection, compared with the control group,the treatment group have a significant differences on symptoms, liver function, indicators of liver fibrosis(P<0.05),but have no significant differences on HBV-DNA load(P>0.05). The efficiency of the treatment group is 84%,and 69.1% is the efficiency of he control group. There was a significant statistical difference(P<0.05).Conclusion:To the decompensated hepatitis B cirrhosis,the treatment group and the control group both have a good effection,and the trestment group have a better effection. Through a long period of observation,it is confirmed that Roumudan Keli have lower toxicity, significant effect of anti-hepatic fibrosis.So the program that using Roumudan Keli and Adefovir dipivoxil to cure the Decompensated hepatitis B cirrhosis is worthy to further promotion.